We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
-15.67%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.15B
AUM Growth
-$535M
Cap. Flow
+$215M
Cap. Flow %
6.83%
Top 10 Hldgs %
73.8%
Holding
31
New
2
Increased
19
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$57M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$46.9M
3
JUNO
Juno Therapeutics, Inc.
JUNO
+$37.5M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$36.5M
5
KITE
Kite Pharma, Inc.
KITE
+$25.2M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$126M
2
INVA icon
Innoviva
INVA
+$5.99M
3
TBPH icon
Theravance Biopharma
TBPH
+$4.68M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$2.42M
5
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$917K

Sector Composition

Rank Sector Weight
1 Healthcare 96.52%
2 Miscellaneous 3.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
26
Prothena Corp
PRTA
$428M
$14.5M 0.46%
+320,000
New +$18.6M
TTPH
27
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$11.1M 0.35%
74,106
-1,250
-2% -$917K
ACHN
28
DELISTED
Achillion Pharmaceuticals
ACHN
$8.84M 0.28%
1,279,340
– –
INVA icon
29
Innoviva
INVA
$1.51B
– –
-331,594
Closed -$5.99M
TBPH icon
30
Theravance Biopharma
TBPH
$885M
– –
-359,190
Closed -$4.68M
RCPT
31
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
– –
-665,272
Closed -$126M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q3 2015 Portfolio in Review

As of Q3 2015, BB Biotech held 31 positions worth $3.15B, down 15% from $3.69B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

BB Biotech deployed $215M of net new capital in Q3 2015, opening 2 new positions and adding to 19 existing holdings. Its largest new stake was Esperion Therapeutics: 908,542 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 93% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $2.42M trimmed.

  • BB Biotech's largest Q3 2015 buy was Esperion Therapeutics: 908,542 shares worth $21.4M.
  • BB Biotech added most to Alexion Pharmaceuticals in Q3 2015, an estimated $46.9M increase.
  • BB Biotech's biggest Q3 2015 reduction was Neurocrine Biosciences, cutting an estimated $2.42M.
  • BB Biotech fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $126M.
  • BB Biotech's ten largest holdings make up 74% of its $3.15B portfolio in Q3 2015.
  • BB Biotech opened 2 new positions and closed 3 in Q3 2015.
  • BB Biotech's portfolio value fell 15% quarter-over-quarter to $3.15B.

Based on BB Biotech's 13F filing for Q3 2015, filed 12 Nov 2015.